Odyssey Health, Inc. - 28 Dec 2023 Form 3 Insider Report for ORAGENICS INC (OGEN)

Reporting relationship
10%+ Owner
Issuer ticker
OGEN
Reported as of
28 Dec 2023
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
16 Jun 2025, 17:54:50 UTC
Next SEC filing
16 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Christine M Farrell, CFO

Key filing fact

Odyssey Health, Inc. filed Form 3 for ORAGENICS INC (OGEN) on 16 Jun 2025.

Key facts

  • This page summarizes Odyssey Health, Inc.'s Form 3 filing for ORAGENICS INC (OGEN).
  • 0 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 16 Jun 2025, 17:54.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001626644 Primary reporting owner

Odyssey Health, Inc.

Relationship
10%+ Owner
Address
2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS
Signature
/s/ Christine M Farrell, CFO
Signature date
16 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OGEN holding

Series F Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
249,623
Date
28 Dec 2023
Ownership
Direct
Footnotes
F1, F3
OGEN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
17,044
Date
28 Dec 2023
Ownership
Direct
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Shares acquired in Asset Sale on December 28, 2023

Footnote F2

Converted on 1:1 basis of Series F Preferred Stock into 19.9% of then outstanding shares of OGEN common stock on December 28, 2023

Footnote F3

Shares reflect the 1:30 reverse stock split on June 3, 2025

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .